CSIMarket
 


Morphic Holding inc   (MORF)
Other Ticker:  
 
 

MORF's Revenue Growth by Quarter and Year

Morphic Holding Inc 's Revenue results by quarter and year




MORF Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 0.00 6.14 9.56 0.00
III Quarter September 0.00 2.06 3.12 0.00
II Quarter June 0.00 60.24 3.85 0.00
I Quarter March 0.52 2.38 3.27 0.00
FY   0.52 70.82 19.80 0.00



MORF Revenue fourth quarter 2023 Y/Y Growth Comment
Morphic Holding inc in the fourth quarter 2023 recorded of $ 0.00 millions.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue growth. While Morphic Holding Inc ' s Revenue no change of % ranks overall at the positon no. 779 in the fourth quarter 2023.




MORF Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -35.77 % - -
III Quarter September - -33.97 % - -
II Quarter June - 1464.68 % - -
I Quarter March -78.15 % -27.22 % - -
FY   -99.27 % 257.68 % - -

Financial Statements
Morphic Holding Inc 's fourth quarter 2023 Revenue $ 0.00 millions MORF's Income Statement
Morphic Holding Inc 's fourth quarter 2022 Revenue $ 6.14 millions Quarterly MORF's Income Statement
New: More MORF's historic Revenue Growth >>


MORF Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 198.06 % 206.41 % -
III Quarter September - -96.58 % -18.96 % -
II Quarter June - 2431.09 % 17.74 % -
I Quarter March -91.53 % -75.1 % - -
FY (Year on Year)   -99.27 % 257.68 % - -




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #93
Overall #779

Revenue Y/Y Growth Statistics
High Average Low
264.59 % 261.16 % 257.72 %
(Mar 31 2023)   (Dec 31 2022)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #93
Overall #779
Revenue Y/Y Growth Statistics
High Average Low
264.59 % 261.16 % 257.72 %
(Mar 31 2023)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Morphic Holding Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MORF's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MORF's IV. Quarter Q/Q Revenue Comment


Morphic Holding Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 68.95 $ 70.81
Y / Y Revenue Growth (TTM) - - - 264.59 % 257.72 %
Year on Year Revenue Growth Overall Ranking # 7 # 69 # 72 # 5 # 17
Seqeuential Revenue Change (TTM) - - - -2.63 % -4.61 %
Seq. Revenue Growth (TTM) Overall Ranking # 779 # 2013 # 54 # 326 # 1376




Cumulative Revenue growth Comment
Morphic Holding Inc realized trailing twelve months of $ 0 millions, in the Dec 31 2023, compare to Revenue of $ 71 millions a year ago.

Morphic Holding inc achieved highest trailing twelve month year on year Revenue growth. While Total ranking has impoved so far to 7, from total ranking in previous quarter at 69.

Revenue TTM Q/Q Growth Statistics
High Average Low
264.59 %
261.16 %
257.72 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 32
Healthcare Sector # 1
Overall # 7

Revenue TTM Y/Y Growth Statistics
High Average Low
264.59 %
261.16 %
257.72 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 93
S&P 500 # 779
Cumulative Revenue growth Comment
Morphic Holding Inc realized trailing twelve months of $ 0 millions, in the Dec 31 2023, compare to Revenue of $ 71 millions a year ago.

Morphic Holding inc achieved highest trailing twelve month year on year Revenue growth. While Total ranking has impoved so far to 7, from total ranking in previous quarter at 69.

Revenue TTM Q/Q Growth Statistics
High Average Low
264.59 %
261.16 %
257.72 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 32
Healthcare Sector # 1
Overall # 7

Revenue TTM Y/Y Growth Statistics
High Average Low
264.59 %
261.16 %
257.72 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 93
S&P 500 # 779




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MORF's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for MORF's Competitors
Revenue Growth for Morphic Holding Inc 's Suppliers
Revenue Growth for MORF's Customers

You may also want to know
MORF's Annual Growth Rates MORF's Profitability Ratios MORF's Asset Turnover Ratio MORF's Dividend Growth
MORF's Roe MORF's Valuation Ratios MORF's Financial Strength Ratios MORF's Dividend Payout Ratio
MORF's Roa MORF's Inventory Turnover Ratio MORF's Growth Rates MORF's Dividend Comparisons



Companies with similar Revenue no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Healthcare Services Group Inc -0.04%$ -0.042 millions
Integra Lifesciences Holdings Corp-0.25%$ -0.247 millions
National Research Corporation-0.37%$ -0.375 millions
The Beauty Health Company-0.63%$ -0.633 millions
3m Company-0.82%$ -0.817 millions
Viatris Inc -1.00%$ -0.998 millions
Quest Diagnostics Inc-1.93%$ -1.929 millions
Koru Medical Systems Inc-2.16%$ -2.161 millions
Envista Holdings Corporation-2.30%$ -2.300 millions
Zynex inc -3.11%$ -3.114 millions
Baxter International Inc -3.55%$ -3.550 millions
Caribou Biosciences Inc -3.63%$ -3.629 millions
Gilead Sciences Inc -3.72%$ -3.722 millions
Lifevantage Corp-3.92%$ -3.921 millions
Avantor Inc -4.02%$ -4.022 millions
Escalon Medical Corp -4.53%$ -4.533 millions
Inovio Pharmaceuticals Inc -4.55%$ -4.553 millions
Optinose Inc -4.76%$ -4.756 millions
Cryoport inc -5.13%$ -5.133 millions
Hookipa Pharma inc -5.38%$ -5.378 millions
Abbvie inc -5.42%$ -5.423 millions
Hologic Inc-5.69%$ -5.688 millions
Encision Inc -6.08%$ -6.083 millions
Biogen Inc -6.20%$ -6.199 millions
Curis Inc -6.62%$ -6.616 millions
Bio rad Laboratories Inc -6.62%$ -6.621 millions
Charles River Laboratories International inc -7.85%$ -7.853 millions
Cara Therapeutics inc -7.88%$ -7.881 millions
Arcus Biosciences Inc -7.89%$ -7.889 millions
Qiagen N v -8.67%$ -8.666 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com